Growth Real, Margins Deferred — the Q2 Trade-Off
Revenue and profit both delivered and beat, but sequential momentum stalled. Management is explicit: reinvestment now, margins later. The question is whether that trade pays off.
Lenskart delivered on headline numbers — revenue and profit both matched or beat prior-call claims. But the quarter tells two stories. Year-over-year, the business is firing: revenue +35.7%, PAT +124.7%, operating margin up 280 basis points. Quarter-over-quarter, it has stalled: revenue +4.8%, PAT +1.8%. The company explains this openly: it is investing hard into volume and brand (John Jacobs, Meller, OWNDAYS, Hustlr, smart glasses) at the expense of near-term profit. That is a deliberate choice, not a miss. The harder question is whether it will pay off.
₹2,845 Cr
+35.7%
₹232 Cr
+124.7%
+4.8%
seasonal moderation
+1.8%
growth decelerating
Claims vs. reality
What changed on this call
Margin timeline pushed to indefinite. Q1 set a long-term target of ~25% EBITDA margin (described as aspirational). Q2 reiterated the target but explicitly deferred it: 'will not put a timeframe on 25%.' Management is clear — margins are secondary to volume and market share for the next several quarters. Current OPM is 21.9%; EBITDA margin (pre-IndAS basis) sits at 13.8%. The gap reflects heavy marketing spend (brand launches, campaigns, Hustlr subsidies) and capex intensity (₹484 Cr H1: ₹187 Cr store network, ₹297 Cr plant).
International economics are proving stronger. International segment posted 29.5% YoY growth (23% constant currency), with EBITDA (pre-IndAS) at ₹127 Cr (+87% YoY) and margin of 10.6% vs 7.3% prior year. Product margin expanded to 77.1%, driven by OWNDAYS and Meller integration. This is a strategic win — it proves the international platform can generate acceptable returns at this scale (38 new stores in H1). Management remains cautious on pace ('slowly and steadily') but Hyderabad capacity expansion is underway.
Hustlr and smart glasses elevated to core strategy. Hustlr (₹500 affordable eyewear) was first mentioned this quarter. Management characterizes it as early-stage but scaling ('Tier 2, Tier 3, logistics to 10K stores'). In-house manufacturing (frames +20% CAGR, lenses +52% QoQ) is the enabler. Lenskart evolv (smart glasses) similarly moved from concept to pilot; 934 stores now have remote optometry capability, enabling 1 store/day openings in Tier 2+. Neither has proven unit economics; both are strategic bets on volume and moat-building.
How the street is positioned
The stock closed at ₹718.80 near its all-time high of ₹760.75, implying the market is pricing in the growth story. Trend is bullish, trading above SMA20/50/200. RSI is 62.5 (neutral, not overbought). Critically, institutional flows are accelerating: FII ownership surged from 3.86% in Q3 FY26 to 12.76% in Q1 FY27 — a +8.5pp jump in two quarters. DII similarly moved from 15.86% to 23.57% (+8.09pp). Bulk deals in late August showed active accumulation by BlackRock, Edelweiss, and Susquehanna in the ₹630–662 range, while a promoter-linked trust (Platinum Jasmine) sold at ₹683 in late September. The institutional inflow pattern suggests confidence in the growth thesis, though the stock's proximity to its all-time high leaves little room for valuation multiple expansion.
YoY revenue +35.7%, PAT +124.7% — sustained momentum confirmed
India SSS +20.8%, pin codes +27.1% — broad-based growth
Operating margin expanded 280bp YoY via in-house manufacturing
International margins +87% EBITDA, 10.6% pre-IndAS — threshold crossing
Remote optometry + AI in 934 stores — structural moat deepening
QoQ PAT +1.8% — growth decelerating sharply
Margin timeline pushed to indefinite — near-term upside capped
FX headwind (₹14.2/RMB) drives 25%+ COGS inflation on imports
Six concurrent brand launches — management bandwidth stretched
Stock at ATH on growth; limited valuation cushion
Risks, ranked by how much they should concern a holder
Forex headwinds (INR/RMB at ₹14.2 vs ₹11–12 prior)
High25%+ COGS inflation on imported frames and lenses. In-house manufacturing (Bhiwadi, Manesar, Thailand) and Tier 2+ India production provide partial offset, but margin compression is structural until INR stabilizes.
Margin deferral with no timeline (25% EBITDA target)
HighManagement explicitly won't quantify when margin expansion resumes. Investors expecting near-term profit leverage will be disappointed. Current OPM 21.9% may plateau before reinvestment moderates.
Execution on simultaneous brand scaling (6+ brands)
MediumJohn Jacobs, Meller, OWNDAYS, Shunya, Hustlr, Lenskart evolv all in growth/launch phase. Management bandwidth and capex spread thin. Success unproven at scale.
Competitive response to Hustlr ₹500 value offering
MediumHustlr targets untapped TAM but draws competitor response. Margin protection depends on in-house manufacturing at 75% automation; economics at ₹500 ASP unproven at 10M+ unit scale.
International expansion logistics and capex intensity
MediumTarget 100M+ pairs, 10K+ stores globally. Hyderabad capacity is acknowledged bottleneck. 38 new stores H1 is aggressive; cash flow covers capex now but scale-up risk is real.
QoQ growth deceleration (PAT +1.8% vs +35.7% YoY)
LowSequential slowdown may reflect H1 front-loading or seasonal moderation post-Diwali. Trailing 12M PAT ₹800 Cr is still strong. But if H2 sustains low QoQ growth, full-year trajectory is at risk.
What to watch next
1 · H2 organic growth trajectory
QoQ PAT +1.8% is a red flag. If Q3 QoQ growth remains single-digit, the growth story is cracking. Look for revenue growth and same-store sales to re-accelerate; if they don't, the margin-deferral thesis loses credibility.
2 · Hustlr scale-up and unit economics proof
Early indicator of whether ₹500 value glasses can drive 10M–100M unit TAM without margin collapse. Next call should show uptick in Hustlr units and AOV metrics that prove economics are viable at planned scale.
3 · FX relief or structural mitigation
If INR/RMB remains at ₹14.2+, in-house manufacturing will be critical. Watch capex allocation to Bhiwadi/Manesar and announcements on India/Thailand lens/frame production scaling. If no relief by Q3, COGS inflation is permanent and margin ceiling is lower.
Lenskart is executing a bet: sacrifice near-term profit for market share and moat-building. The numbers support the growth half — revenue, volumes, international economics all moving. The question is whether the cost of reinvestment is worth it. Management is betting on Tier 2+ densification, Hustlr scale, international inflection, and smart glasses adoption to deliver 25%+ EBITDA margins, explicitly refusing to quantify a timeline. Institutions are betting too — FII ownership +850bp in two quarters signals confidence. But the stock is at its all-time high and margins are deferred indefinitely. Risk-reward is balanced, not convex. Growth is steady; margins are contingent. The number to track is organic ROCE — if capital deployed in Hustlr, international, and evolv generates 18%+ returns, the deferral thesis holds. If returns stall, the stock will not appreciate until reinvestment slows. At ₹718, this is a disciplined hold for long-term growth believers, not a near-term trade.
Informational and educational content only. Not investment advice.